



Rapid Oligonucleotides QC with Automated High Resolution ESI-LCMS and BioPharma Compass

Oligonucleotides – sequences of nucleotides (RNA and DNA) – are vital research tools that have a wide range of applications in genetic testing, research, and forensics.

Abstract

Common applications include artificial gene synthesis, primers for polymerase chain reaction (PCR), DNA sequencing, molecular cloning and as molecular probes. Oligonucleotides are typically made in the laboratory by a solid-phase chemical synthesis process using phosphoramidite chemistry. Modern synthesis platforms and high-throughput automation systems support robust oligonucleotide manufacturing capabilities. Despite these advances, oligonucleotide synthesis is a complex process, involving hundreds of sequential chemical reactions. Quality control of precise and accurate synthesis is of high importance as it is ensuring that synthesis by-products or process contaminants are within acceptable limits.

Keywords: Oligo QC, maXis II QTOF, BioPharma Compass



Mass Spectrometry (MS) is the technology of choice for analyzing oligonucleotides. It provides confirmation that the correct sequence has been synthesized with high mass accuracy and enables sensitive detection of low levels of by-products generated during synthesis process such as truncated or deleted sequences, depurination and incomplete removal of protecting groups. Mass spectrometry techniques and integrated software solutions facilitate oligonucleotide quality control by assessing oligonucleotide identity in a high-throughput manner.

Here we describe an automated UPLC-MS method for the quality control of synthetic oligonucleotides. The automated workflow is implemented using BioPharma Compass[®] software which encompasses data acquisition, processing and reporting using a seamless workflow solution.

Introduction

Dedicated software, such as BioPharma Compass (Bruker Daltonics), enables the routine analysis of biopharmaceuticals including oligonucleotides and offers LC-MS workflows with automated measurements and report generation. BioPharma Compass comprises a



Figure 1: BioPharma Compass data flow



Figure 2: Elute HPLC gradient and maXis II parameters

secure server that communicates with the client PC and the instrument acquisition PC. The user can set up sample batches for acquisition; the data are acquired and can be automatically moved to the data storage and processing station to preserve the data integrity and security. The results are accessible to the user from the BioPharma Compass server. The entire workflow is fully supported by 21 CFR Part 11 compliance features.

	ss - Demo - Iocalho									
	ヨー 今門									
Import Meth	ods									
HvStar is run	ning									
> 😪 New Batch	1									
Queue Batch	h									
Station Statu	IS S									
Batches Pers	pective									
Submitter:	Demo User								1	
Subfolder:	Optional subfolder f	or this batch (e.g.)	COA\ProjectName	2)					ī	
Batch Name:	RNA OC			,					i i	
Description	Ontional description	of the batch							-	
Description:	Optional description	of the batch.								
	-	-		-		-				
Workflow:	O MAM Protein Scr	eening O Top-D	own Sequencing	O Peptide M	lapping	O MAM Peptide	Screening 💿	Multi Target Screening		
Workflow: Method(s):	MAM Protein Scr Single Method	eening O Top-D	own Sequencing	O Peptide M	lapping	O MAM Peptide	Screening	Multi Target Screening		
Workflow: Method(s):	MAM Protein Scr Single Method	eening O Top-D Oligo Standard	own Sequencing	O Peptide M	lapping	O MAM Peptide !	Screening 💿	Multi Target Screening	Ī	
Workflow: Method(s):	MAM Protein Scr Single Method	eening O Top-D Oligo Standard	own Sequencing	O Peptide M	lapping	O MAM Peptide	Screening Place Samp	Multi Target Screening		
Workflow: Method(s):	MAM Protein Scr Single Method	eening O Top-D Oligo Standard	own Sequencing	O Peptide M	lapping	O MAM Peptide	Screening Place Samp Place your s	Multi Target Screening v	ositions and mark th	em as placed usin
Workflow: Method(s):	MAM Protein Scr Single Method	eening O Top-D Oligo Standard	lown Sequencing	O Peptide M	lapping	O MAM Peptide :	Place Samp Place your s the check but	Multi Target Screening) ositions and mark th	em as placed usin
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial O Wellplate	eening OTop-D Oligo Standard	own Sequencing	O Peptide M	tapping	O MAM Peptide :	Screening Place Samp Place your s the check be Dataset ID	Multi Target Screening	ositions and mark th	em as placed usin Dataset Not
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial Wellplate	eening O Top-D Oligo Standard	own Sequencing	O Peptide M	tapping File	O MAM Peptide :	Place Samp Place yours the check by Dataset ID 900	Multi Target Screening	ositions and mark th Tray Position	em as placed usin Dataset Not
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial O Wellplate	eening O Top-D Oligo Standard	Acquisition Table	O Peptide M	tapping File	O MAM Peptide :	Place Samp Place Samp Place yours the check by Dataset ID 900 2 810	Multi Target Screening es ample or trays into the given poxes. Method Name RNA_25min (Olig RNA_25min (Olig)	ositions and mark th Tray Position 1 2	em as placed usin Dataset Not 2 0.7
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial Wellplate	eening O Top-D Oligo Standard	own Sequencing	O Peptide M	tapping File	O MAM Peptide !	Place Samp Place Samp Place yours the check b Dataset ID 900 910 910	Multi Target Screening	Disitions and mark th Tray Position 1 2 3	em as placed usin Dataset Not 2 0.7 2
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial Vial Wellplate	eening O Top-D Oligo Standard Import J	Acquisition Table	O Peptide M	happing File < Back	O MAM Peptide :	Place Samp Place yours the check b Dataset ID 900 810 59 90 90 90 90 90 90 90 90 90 90 90 90 90	Multi Target Screening	Tray Position 1 2 3 4	em as placed usin Dataset Not 2 0.7 2 3
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial Vial Wellplate	eening O Top-D Oligo Standard	Acquisition Table	O Peptide M	File Sack	O MAM Peptide :	Place Samp Place Samp Place yours the check by Dataset ID 900 910 910 910 910 910 910 910 910 910	Multi Target Screening	ositions and mark th Tray Position 1 2 3 4 5	em as placed usin Dataset Not 2 0.7 2 3 0.3
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial Wellplate	Oligo Standard	own Sequencing	O Peptide M	Tapping File < Back	O MAM Peptide :	Place Samp Place your s the check by Dataset ID 900 910 910 910 910 910 910 910 910 910	Multi Target Screening	Tray Position 1 2 3 4 5 6	em as placed usin Dataset Not 2 0.7 2 3 0.3 0.7
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial Vial Wellplate	Oligo Standard	own Sequencing	O Peptide M	File < Back	O MAM Peptide : Next >	Place Samp Place yours the check b Dataset ID 900 910 910 910 910 910 910 910 910 910	Multi Target Screening ample or trays into the given prozes. Method Name RNA_25min (Olig RNA_25min (Olig RNA_25min (Olig RNA_25min (Olig RNA_25min (Olig RNA_25min (Olig RNA_25min (Olig RNA_25min (Olig RNA_25min (Olig)	Tray Position 1 2 3 4 5 6 7	em as placed usin Dataset Not 2 0.7 2 3 0.3 0.7 0.7
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial Vial Wellplate	Oligo Standard	Acquisition Table	O Peptide M	File < Back	O MAM Peptide : Next >	Place Samp Place Samp Place yours the check b Dataset ID 900 Ø10 Ø290 Ø10 Ø390 Ø10 Ø390 Ø10 Ø390 Ø10 Ø390 Ø10 Ø390 Ø45 Ø45 Ø487	Multi Target Screening	ositions and mark th Tray Position 1 2 3 4 5 5 6 7 8	em as placed usin Dataset Not 2 0.7 2 3 0.3 0.7 0.7 0.7
Workflow: Method(s): Sample Container:	MAM Protein Scr Single Method Vial Wellplate	eening O Top-D Oligo Standard	Acquisition Table	O Peptide M	File < Back	O MAM Peptide : Next >	Place Samp Place Samp Place yours the check bi Dataset ID 900 910 910 92 61 952 628 485 952 962 962 953 9542 9542 <t< td=""><td>Multi Target Screening ample or trays into the given prozes. Method Name RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_</td><td>Tray Position 1 2 3 4 5 6 6 7 8 9</td><td>em as placed usin Dataset Not 2 0.7 2 3 0.7 0.7 0.7 0.7 0.7 0.7</td></t<>	Multi Target Screening ample or trays into the given prozes. Method Name RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_ RNA_25min (Olig_	Tray Position 1 2 3 4 5 6 6 7 8 9	em as placed usin Dataset Not 2 0.7 2 3 0.7 0.7 0.7 0.7 0.7 0.7

Figure 3: Automated acquisition set-up in BioPharma Compass

Experimental

A fully automated acquisition and processing workflow for rapid oligonucleotide QC was defined in BioPharma Compass. The LCMS method set included the LC separation and the detection by mass spectrometry. The separation was carried out on a Bruker Elute UPLC system (Bruker Daltonics) equipped with a BEH C4 1.7 µm 1x100 mm column at a flow rate of 500 μ L/min and a temperature of 80°C. The mobile phases were A - 1% HFIP, 0.1% Hexylamine in water and B-50% ACN + 50% MeOH. One µg of synthetic oligonucleotide samples dissolved in water were injected on column. The detection was performed on a Bruker maXis II ETD UHR QTOF operated in negative ion mode. The LC gradient and MS source parameters are shown in Figure 2.

The Automated Acquisition button in the blue BioPharma Compass Ribbon allowed straightforward setting up of sample batches for acquisition. The simple interface required minimal input from the user for a batch name, workflow and method as seen in Figure 3. A LIMS generated worklist can be directly imported. Once the samples are placed in the autosampler positions, the acquisition of the queued batch is initiated.

The processing view in BioPharma Compass allows monitoring of the submitted queue. As the data is acquired, the data mover feature automatically moves it to the data storage and processing station preventing direct user access, thus preserving data integrity and maintaining security. Spectra were obtained across the chromatographic peaks and charge deconvoluted using a Maximum Entropy algorithm yielding neutral average mass molecular weights.

Туре	9	Name	User	Proce	Status		Start	Finis	
Multi Target Screening		RNA QC-[113]	Dem.	. 0/10	running	2020-0		5	
			D	Ch. d	5	NI			
#	Algorithm / Metho	d Status	Pr	Start	FINISh	Name	UF	(L	wessage
0	Oligo Standard_1.0	waiting		2020		400-[141]			
9	Oligo Standard_1.0) waiting		2020		482-[140]			
8	Oligo Standard_1.0) waiting		2020		487-[139]			
7	Oligo Standard_1.0) waiting		2020		628-[138]			
6	Oligo Standard_1.0) waiting		2020		562-[137]			
5	Oligo Standard_1.0) waiting		2020		485-[136]			
4	Oligo Standard_1.0) waiting		2020		61-[135]			
3	Oligo Standard_1.0) waiting		2020		59-[134]			
2	Oligo Standard_1.0) waiting		2020		810-[133]			
1	Oligo Standard 1.0) running	0 %	2020		900-[132]			idle

Figure 4: Processing view shows status of queued batch

Results

BioPharma Compass has an interactive user-friendly interface that allows users to see the results at-a-glance. Several views highlight different aspects of the data such as the result tables, chromatograms and spectra. Screening of batches is facilitated through similarity scores and mass accuracy attributes which are the basis for an automatic pass/fail assessment. Reports utilize color coding of results and charts for rapid reviewing.

The Result table summarizes the analyses in the sample table including the MAM reporting icon **...**, base peak of the spectrum and mass difference to the base peak. Clicking one of the rows in the results table shows the expected table view seen in Figure 5 with the detailed modifications for that specific analysis. The relative intensities of the sample versus the reference allow comparison of the measured profile to the reference profile.

		Result	Position	Base Peak	∆Base Peak	BatchNu	Injection	Mr (LIMS) Formul	a or Mr a	
			BH4	6439.2	-1.	0 486	0.7	6439.26	C205H	258N83O	
			BG4	6653.2	-0.	2 482	0.7	6653.39	6653.4		
			BF3	7304.8	-1.	0 487	0.7	7304.84	C234H	296N90O	
			BE5	4906.1	-1.	2 628	0.7	4906.25	C156H	197N63O	
			BE2	7967.3	0.	0 562	0.7	7967.25	7967.3		
			BD2	9134.1	0.	1 485	0.3	9134.02	9134.0		
		*	BB7	6449.2	-0.	1 061	3	6449.25	6449.3		
۲	Result	Position	Base Peak N	1r[Da] ∆Ba	ise Peak Mr [Da]	BatchNumbe	r Injection Vol	ume [uL]	Mr (LIMS)	Formula or Mr avg	
	12	BB7	6	449.2	-0.1	061	3		6449.25	6449.3	
xp	ected Uni	dentified									
Fo	rmula	Annotat	ion	Mr Sample	Δ Mr [Da]	Int. [a.u.]	Rel. Int. Ref [%] Rel. In	t. Sample [%] Rt Sample [min]	Confirm
64	49.25 Da	2xDIEA		6713.6	6.0	9.098E+02	0.1		0.3	0.60	Yes
64	49.25 Da	Depurin	ation_dA	6315.0	0.7	3.883E+04	0.1		14.1	0.60	Yes
64	49.25 Da	Depurin	ation_dG	6293.7	-4.5	3.851E+04	0.1		14.0	0.60	Yes
64	49.25 Da	Depyrin	nidination_dC	6335.4	-2.9	6.076E+03	0.1		2.2	0.60	Yes
64	49.25 Da	DIEA		6578.3	-0.2	1.018E+03	0.1		0.4	4 0.60	Yes
64	49.25 Da	M		6449.2	-0.1	1.901E+05	99.5	5	69.0	0.60	Yes

Figure 5: Results summary table and detailed expected results table showing fragmentation products and adducts resulting from the chromatographic additives.

		chiomatogi	ann reaks	
Sample Position: BB7 Sa	ample ID: 0	61		
Method Attribute	Narrow	Wide	Sample Result	Unit
Base peak as expected	≥ 100.0	< 70.0	100.0	Rel. int. [%] vs. base peak
Target Profile Matching	≥ 0.680	< 0.600	0.961	Similarity [cosine score]
Mass Accuracy [Da]	< 7.00	≥ 10.00	1.81	Da
Intensity Coverage	≥ 60.0	< 40.0	80.4	Rel. int. [%] of all target signals

Figure 6: Multi-attribute table provides a legend to each individual sample result.



Figure 7: Chromatogram and spectrum views



Figure 8: Report from an example dataset

The Multi-Attributes window (Figure 6) shows that this sample has the right base peak, the target profile matches expectations, good mass accuracy and intensity coverage.

The chromatogram window shows the highlighted TIC and details about the Rt, area and intensity. The spectra windows allow a detailed inspection of the raw spectrum and the Maximum Entropy deconvoluted spectrum. A report was generated, summarizing the workflow acquisition and processing parameters with details about the chromatogram, spectra, summary tables and multi-attribute pass-fail criteria.

Conclusion

- BioPharma Compass enabled straightforward automated acquisition and processing of oligonucleotide QC batches in a seamless workflow that included LCMS acquisition methods, batch submission and queuing, result viewing and report generation.
- The multi-attribute screening workflow allows users to obtain critical information about synthesis process modifications for rapid QC of the final product.





You are looking for further Information? Check out the link or scan the QR code for more details.

http://www.bruker.com/massspectrometry



References

[1] Tech Note: Automated High-Throughput Oligo QC: From Automated Sample Preparation to MALDI Spectra Assessment, 07-2020 https://www.bruker.com/fileadmin/user_upload/8-PDF-Docs/Separations_MassSpectrometry/Literature/TechNotes/1877861_ TN-50_Automated_High_Throughput_Oligo_QC_ebook.pdf

[2] Flash Note: The Complete Solution: Oligonucleotide, 03,2019 <u>https://www.bruker.com/fileadmin/user_upload/8-PDF-Docs/Separations_MassSpectrometry/Literature/TechNotes/FN-007_ Oligonucleotides_03-2019.pdf</u>

For Research Use Only. Not for Use in Clinical Diagnostic Procedures.

Bruker Daltonik GmbH

Bruker Scientific LLC

Bremen · Germany Phone +49 (0)421-2205-0 Billerica, MA · USA Phone +1 (978) 663-3660